Glaxo bribery claims stretch to Syria

|By:, SA News Editor

GlaxoSmithKline (NYSE:GSK) is now facing corruption claims in Syria, where it's has been accused of bribery to secure business.

The drugmaker is investigating the claims which date back to 2010 after a whistleblower's email was sent to the company.

Syria is now the sixth country to be investigated by Glaxo for smaller-scale bribery claims compared to the $480M Chinese allegations which have plagued the company since last July.

GSK -0.2% AH